We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celanese (CE) to Raise Engineered Materials Products Prices
Read MoreHide Full Article
Celanese Corporation (CE - Free Report) will hike the prices for engineered materials products. The rise will be effective Apr 1, 2018 or as contracts permit.
Per the company, prices will increase for Hostaform and Celcon Polyacetal (POM) grades, PBT (such as Impet PET, Celanex PBT and Vandar PBT Alloys), Laprene (TPE-S), Forprene (TPV) and Forflex (TPO) grades, LCP (Thermx, Vectra, Zenite) grades and GUR ultra-high molecular weight polyethylene grades. Moreover, the prices of these products will increase in the Americas, Europe and Asia.
Notably, Celanese is the world’s leading supplier of GUR and polyacetal products. It is also the only supplier with global production facilities that provides local supply to all regions of the world.
Celanese is taking appropriate pricing actions amid a volatile raw material pricing environment. The company’s strategic measures, including operational cost savings through productivity actions and pricing initiatives, are likely to boost its earnings in 2018.
The stock has lost 6.9% over the last three months, outperforming the industry’s 8.3% decline.
Celanese recently raised its earnings guidance for 2018, citing a stronger start to the year across its Acetyl Chain and Advanced Engineered Materials businesses. The company now envisions adjusted earnings per share growth in the 12-16% range from the prior-year quarter, up from its earlier view of 10-14% growth.
Celanese is witnessing better-than-expected performance in all of its businesses. The company’s Acetyl Chain unit continues to gain momentum globally while improved pricing and strong demand trends in its Advanced Engineered Materials business are contributing to its earnings. Celanese plans to provide more details on the same during first-quarter 2018 earnings call.
LyondellBasell has an expected long-term earnings growth rate of 9%. Its shares have moved up 13.1% over a year.
CF Industries has an expected long-term earnings growth rate of 6%. Its shares have gained 23% over a year.
Daqo New Energy has an expected long-term earnings growth rate of 7%. Its shares have rallied 146.9% over a year.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
Celanese (CE) to Raise Engineered Materials Products Prices
Celanese Corporation (CE - Free Report) will hike the prices for engineered materials products. The rise will be effective Apr 1, 2018 or as contracts permit.
Per the company, prices will increase for Hostaform and Celcon Polyacetal (POM) grades, PBT (such as Impet PET, Celanex PBT and Vandar PBT Alloys), Laprene (TPE-S), Forprene (TPV) and Forflex (TPO) grades, LCP (Thermx, Vectra, Zenite) grades and GUR ultra-high molecular weight polyethylene grades. Moreover, the prices of these products will increase in the Americas, Europe and Asia.
Notably, Celanese is the world’s leading supplier of GUR and polyacetal products. It is also the only supplier with global production facilities that provides local supply to all regions of the world.
Celanese is taking appropriate pricing actions amid a volatile raw material pricing environment. The company’s strategic measures, including operational cost savings through productivity actions and pricing initiatives, are likely to boost its earnings in 2018.
The stock has lost 6.9% over the last three months, outperforming the industry’s 8.3% decline.
Celanese recently raised its earnings guidance for 2018, citing a stronger start to the year across its Acetyl Chain and Advanced Engineered Materials businesses. The company now envisions adjusted earnings per share growth in the 12-16% range from the prior-year quarter, up from its earlier view of 10-14% growth.
Celanese is witnessing better-than-expected performance in all of its businesses. The company’s Acetyl Chain unit continues to gain momentum globally while improved pricing and strong demand trends in its Advanced Engineered Materials business are contributing to its earnings. Celanese plans to provide more details on the same during first-quarter 2018 earnings call.
Celanese Corporation Price and Consensus
Celanese Corporation Price and Consensus | Celanese Corporation Quote
Zacks Rank & Stocks to Consider
Celanese currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks worth considering in the basic materials space are LyondellBasell Industries N.V. (LYB - Free Report) , CF Industries Holdings, Inc. (CF - Free Report) and Daqo New Energy Corp. (DQ - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
LyondellBasell has an expected long-term earnings growth rate of 9%. Its shares have moved up 13.1% over a year.
CF Industries has an expected long-term earnings growth rate of 6%. Its shares have gained 23% over a year.
Daqo New Energy has an expected long-term earnings growth rate of 7%. Its shares have rallied 146.9% over a year.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>